Phase I/II clinical trials initiated by Martin-Luther-Universität Halle-Wittenberg was designed to explore the feasibility, safety, and efficacy of combining TCP with all-trans retinoic acid (ATRA) in relapsed or refractory AML.245 And another phase I clinical trial sponsored by University of Miami has been completed in 2020, it indicated that these two drugs combination was safe and effective, and LSD1 inhibition can sensitize AML cells to ATRA. Here, KDM1A is linked to acute myeloid leukemia.